Abstract 1688P
Background
Elderly patients are disproportionately burdened with cancer morbidity and mortality. The disease and its treatment are complicated by ageing-related issues such as loss of loved ones, socioeconomic changes, and the presence of comorbidities. Thus, they are at high risk of psychosocial distress and poor health-related quality of life. There is a significant paucity of data on the prevalence and determinants of psychosocial distress among elderly patients with cancer in Nigeria, necessitating this study.
Methods
This descriptive cross-sectional study was conducted among 296 patients aged 60 years and older with cancer attending the NSIA LUTH Cancer Centre. Data collection was interviewer-based using a structured questionnaire along with the Depression, Anxiety, and Stress Scale 21-item (DASS-21) and Functional Assessment of Chronic Illness Therapy—Spiritual Well-Being 12 (FACITsp-12). The association between different variables was assessed by chi square. Statistical analysis was done with IBM Statistical Package for Social Sciences Version 25, and a p value of <0.05 was regarded as significant.
Results
The prevalence of psychosocial distress among the respondents was depression (19.9%), anxiety (46.0%), and stress (3.0%). The majority of the respondents (77.7%) had intermediate/high spiritual levels. The prevalence of depression was significantly higher in those with comorbidities and those receiving chemotherapy. A high spiritual level was also significantly associated with a lower level of depression, anxiety, and stress.
Conclusions
We found a higher prevalence of psychosocial distress among patients who received chemotherapy as part of their treatment and also among those with comorbidities. A higher spiritual level was found to be associated with a reduced level of psychosocial distress. Therefore, there is a need to screen patients with comorbidities and those on chemotherapy for psychosocial distress in order to identify those in need of additional psychological and social work support. A holistic approach that integrates psychosocial and spiritual care into cancer treatment not only alleviates the emotional burden but also contributes to improved overall well-being and treatment outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Z. A. Ogunjimi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1656TiP - The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT)
Presenter: Sarah Howlett
Session: Poster session 11
1658TiP - The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT)
Presenter: Minal Padden-Modi
Session: Poster session 11
1659TiP - A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer
Presenter: Mark Stein
Session: Poster session 11
1660TiP - First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Raanan Berger
Session: Poster session 11
1661TiP - SEGNO: An exploratory study of the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer
Presenter: Haichao Huang
Session: Poster session 11
1662TiP - HARMONY: A phase II study of niraparib (N)/abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa)
Presenter: Qian Qin
Session: Poster session 11
1664P - Early integration of psycho-oncology in cancer care: A model of care from a quaternary care government hospital in India and its patient related outcomes
Presenter: Niharika Bisht
Session: Poster session 11
1665P - Awareness of illness, psychological difficulties, and resources across life ages in early stage and metastatic cancer patients
Presenter: Raffaela Sartori
Session: Poster session 11